Cancer-Associated Thrombosis (CAT). research hub

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess Efficacy and Safety of REGN7508, a Monoclonal Antibody Against FXI, for Primary Prophylaxis of Cancer-Associated Thrombosis for Participants with Solid Tumors Undergoing Cancer Treatment (ROXI-CAT-I)

This study is testing a new medicine, REGN7508, to see if it can prevent blood clots in people with cancer who are having treatment. It compares the medicine to a dummy treatment (placebo) to see how well it works and if it's safe.